NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $87.32 +0.87 (+1.01%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Lantheus Stock (NASDAQ:LNTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lantheus alerts:Sign Up Key Stats Today's Range$85.24▼$88.5250-Day Range$76.22▼$116.6952-Week Range$50.20▼$126.89Volume1.46 million shsAverage Volume1.02 million shsMarket Capitalization$6.07 billionP/E Ratio14.53Dividend YieldN/APrice Target$122.50Consensus RatingModerate Buy Company OverviewLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More… BREAKING: NVDA loses $175 billion in 8 minutes (Ad)It's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, with annual revenue up nearly 100%. So why did the stock abruptly plunge following the earnings release – losing $175 billion in just 8 minutes?Things are about to get even stranger. Lantheus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks92nd Percentile Overall ScoreLNTH MarketRank™: Lantheus scored higher than 92% of companies evaluated by MarketBeat, and ranked 102nd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLantheus has only been the subject of 3 research reports in the past 90 days.Read more about Lantheus' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth2.52% Earnings GrowthEarnings for Lantheus are expected to grow by 2.52% in the coming year, from $5.96 to $6.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 14.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 14.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.18.Price to Book Value per Share RatioLantheus has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.03% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Lantheus has recently decreased by 1.41%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.67 Percentage of Shares Shorted6.03% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Lantheus has recently decreased by 1.41%, indicating that investor sentiment is improving. News and Social Media3.9 / 5News Sentiment1.05 News SentimentLantheus has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Lantheus this week, compared to 7 articles on an average week.Search Interest28 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows7 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Stock News HeadlinesLantheus To Repurchase Up To $250 Mln Of SharesNovember 21 at 10:09 AM | markets.businessinsider.comWhy Lantheus Holdings Stock Won Big on WednesdayNovember 20 at 6:54 PM | fool.comWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.November 22, 2024 | InvestorPlace (Ad)Lantheus Holdings, Inc. Authorizes $250 Million Stock Repurchase Program to Enhance Shareholder ValueNovember 20 at 8:01 AM | quiverquant.comLantheus Announces Share Repurchase ProgramNovember 20 at 1:00 AM | globenewswire.comLantheus Holdings' (NASDAQ:LNTH) Promising Earnings May Rest On Soft FoundationsNovember 13, 2024 | finance.yahoo.comLantheus to Present at the Jefferies London Healthcare ConferenceNovember 13, 2024 | globenewswire.comBuy Rating Reaffirmed for Lantheus Amid Discounted Valuation and Promising Growth CatalystsNovember 13, 2024 | markets.businessinsider.comSee More Headlines LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $62.00 on January 1st, 2024. Since then, LNTH stock has increased by 40.8% and is now trading at $87.32. View the best growth stocks for 2024 here. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Wednesday, July, 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by $0.07. Lantheus's revenue for the quarter was up 22.5% compared to the same quarter last year. When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' top institutional shareholders include Janus Henderson Group PLC (5.16%), Geode Capital Management LLC (2.42%), Westfield Capital Management Co. LP (2.18%) and Reinhart Partners LLC. (1.79%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden, Minnie Baylor-Henry and Carol Walker. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/31/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees834Year FoundedN/APrice Target and Rating Average Stock Price Target$122.50 High Stock Price Target$175.00 Low Stock Price Target$100.00 Potential Upside/Downside+39.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$6.01 Trailing P/E Ratio14.57 Forward P/E Ratio14.69 P/E GrowthN/ANet Income$326.66 million Net Margins28.57% Pretax Margin38.09% Return on Equity44.29% Return on Assets23.52% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.56 Sales & Book Value Annual Sales$1.30 billion Price / Sales4.70 Cash Flow$7.43 per share Price / Cash Flow11.78 Book Value$16.97 per share Price / Book5.16Miscellaneous Outstanding Shares69,530,000Free Float68,484,000Market Cap$6.09 billion OptionableOptionable Beta0.51 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:LNTH) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.